Effect of 2-year treatment with Omalizumab in severe atopic asthma in real clinical practice

Abstract

To evaluate the clinical efficacy and safety of long-term anti-IgE therapy in patients with severe uncontrolled atopic asthma. In Chelyabinsk from November 2016 47 patients regularly receive omalizumab therapy - 8 men (17.02%) and 39 women (82.98%), the average age was 53.5×10.2 years, the duration of the asthma - 22.7×11.5 years. All patients have associated allergic pathology: allergic rhinitis - 100%, pollinosis - 79.4%, food allergy - 44.1%, atopic dermatitis - 26.5%. The level of total IgE in the blood is from 72 to 787 IU/ml. High sensitization to household (87.2%), epidermal (61.7%), pollen (74.5%) allergens was detected. All patients received basic combination therapy of inhaled corticosteroids and LABA in high doses, 38 (80.85%) additionally took systemic corticosteroids, 26 (55.3%) anti-leukotriene and 16 (34.04%) used tiotropium. For 24 months anti-IgE-therapy there were no severe exacerbation of asthma, there were no hospitalizations, canceled systemic corticosteroids for basic therapy. All patients showed a decrease of daytime (by 88.1%) and night (by 98.2%) symptoms, on 81.9% reduced the need of SABA. Over 2 years of therapy the quality of life improved significantly according to the AST test (5.62×0.91 vs 20.93×2.11, p<0.001) and the ACQ-7 (3.64×0.52 vs 1.22×0.66, p<0.001). 76.6% patients have no symptoms of allergic rhinitis. Improved the lunf function: initially FEV1=63.15×2.9%, after 24 months treatment with omalizumab FEV1=90.21×1.58%, p<0.001.